Allogeneic Stem Cell Transplantation Demonstrates Lasting Remissions Among Patients With MCL, Including With TP53 Mutations
Allogeneic stem cell transplantation (alloSCT) demonstrated long-term remissions and potential curative effects among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), including patients with TP53-mutated disease, according to an extended follow-up study published in Leukemia & Lymphoma.
“Patients with TP53-mutated disease have poor outcomes with standard approaches,” stated Thomas E Lew, Peter MacCallum Cancer Centre, and Royal Melbourne Hospital, Melbourne, Australia, and coauthors stated. They added, “follow-up among patients with TP53-mutated disease was limited” despite previous reports that alloSCT achieved durable remissions among patients with MCL.
In this study, Dr Lew and coauthors presented extended follow-up data for both the overall cohort (n = 36) and a subset of patients with TP53-mutated disease (n = 13). The median follow-up for the overall cohort was 10.8 years, and the TP53-mutated subset had a median follow-up of 4.2 years. Survival analyses were conducted to estimate overall survival rates and evaluate the impact of alloSCT on disease remission and post-relapse survival.
The estimated overall survival rates were 56% at 10 years for the overall cohort and 59% at 4 years for the TP53-mutated subset. Patients with TP53-mutated disease experienced no relapses beyond 6 months post-transplant, indicating the potential impact of alloSCT in this subset. Study authors noted that survival following disease relapse post-alloSCT was poor, with a median survival of 2.1 years.
Dr Lew and coauthors concluded, “These data confirm that alloSCT can be curative in MCL, including patients with TP53-mutated disease, and should be considered for earlier utilization in this subgroup for whom conventional chemoimmunotherapy is ineffective.”
Source:
Lew TE, Scheffer Cliff ER, Dickinson M, et al. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease. Leukemia & Lymphoma. Published online August 2, 2023; doi: 10.1080/10428194.2023.2241095
